Medical Cannabis for MS UK — Spasticity, Pain & Sleep

Multiple sclerosis affects approximately 130,000 people in the UK, and spasticity — involuntary muscle stiffness and spasms — is one of the most debilitating and treatment-resistant symptoms. Medical cannabis has become an increasingly important tool in the management of MS-related spasticity, with both regulatory-approved options and broader prescription cannabis available through specialist clinics under MHRA Schedule 2 provisions.

Sativex, NICE Guidelines and the UK Regulatory Landscape

Sativex (nabiximols) remains the only cannabis-based medicine with a full UK product licence specifically indicated for MS-related spasticity. It is a 1:1 THC:CBD oromucosal spray, licenced by the MHRA, and is recommended by NICE (TA559) for adults with moderate-to-severe MS spasticity that has not responded adequately to other antispasticity agents. However, NHS funding for Sativex is inconsistently available across England, Scotland and Wales — many patients who meet the clinical criteria cannot access it through their NHS neurologist and are turning to private medical cannabis clinics instead.

Beyond Sativex, GMC-registered specialists at licensed UK medical cannabis clinics can prescribe unlicensed cannabis-based medicinal products (CBMPs) under the MHRA's Schedule 2 framework for MS patients who have not responded to standard treatments. The clinical evidence base for this broader use is growing: the 2022 CLEAR-MS study and Project TWENTY21 data both report significant spasticity reduction in MS patients receiving prescribed cannabis flower and oils.

NICE guidance on MS management (NG220, updated 2022) notes that clinicians should consider cannabis-based products for adults with refractory spasticity. This creates a clear clinical pathway for MS patients who have failed two or more antispasticity medications (typically baclofen and tizanidine) to seek specialist referral for medical cannabis.

THC:CBD Balance, Dosing and Mechanism of Action

For MS spasticity, the 1:1 THC:CBD ratio used in Sativex is considered the clinical benchmark. This balance matters because CBD modulates some of THC's psychoactive effects while contributing its own anti-inflammatory and neuroprotective properties. Both compounds appear to act synergistically on the endocannabinoid system's CB1 and CB2 receptors in muscle tissue and the spinal cord, reducing the hyperexcitability that drives spasm.

Patients new to cannabis-based treatment for MS should expect a titration period of 4–6 weeks before optimal spasticity relief is achieved. A typical starting regime for an MS patient might be:

• Week 1–2: 2.5 mg THC / 2.5 mg CBD twice daily (morning and evening)
• Week 3–4: Increase to 5 mg THC / 5 mg CBD twice daily if tolerated
• Week 5+: Adjust based on spasticity assessment scores (NRS 0–10) and clinician review
• Many MS patients stabilise at 15–30 mg THC equivalent per day total

Muscle spasms that are nocturnal in character respond particularly well to an evening dose of indica-dominant flower or a bedtime oil, while daytime spasticity may require a more balanced sublingual oil to avoid cognitive sedation during waking hours.

UK Clinics for MS Patients and Patient Experiences

Several UK medical cannabis clinics have developed particular expertise in neurological conditions including MS. Clinics with documented MS experience include Releaf, Curaleaf Clinic and Drug Science's Project TWENTY21 partner network. When seeking a referral, MS patients should bring documentation of their diagnosis, current medication history and evidence of insufficient response to at least two conventional antispasticity treatments — this strengthens the case for CBMP prescription under NICE and MHRA criteria.

Patient experiences reported through MS Society UK surveys and the Project TWENTY21 dataset consistently highlight improvements in sleep quality alongside spasticity reduction — these two symptoms are closely linked, as nocturnal spasms are a major cause of MS-related sleep disruption. Patients also report reduced reliance on benzodiazepines and other sedating antispasticity drugs after commencing cannabis treatment, though any medication changes must be made in consultation with the prescribing specialist and the patient's neurologist.

For chronic pain associated with MS, additional products beyond a 1:1 ratio may be appropriate — discuss this with your specialist, as the optimal cannabinoid profile for pain differs from that for pure spasticity management. Use our product comparison tool to review the 1:1 balanced products currently available through UK licensed suppliers.